https://9690a.iqanda-cme.com/ 2019-06-06T22:44:17+0000 weekly 1 https://9690a.iqanda-cme.com/about-iqanda-interventional-cardiology 2019-04-10T00:35:12+0000 weekly 0.8 https://9690a.iqanda-cme.com/interventional-cardiology 2019-08-17T02:21:37+0000 weekly 0.8 https://9690a.iqanda-cme.com/submit-a-question 2019-08-02T05:55:44+0000 weekly 0.8 https://9690a.iqanda-cme.com/videos/based-on-odyssey-outcomes-which-patients-in-an-interventional-cardiology-practice-do-you-believe-will-benefit-most-from-pcsk9-inhibition1 2019-03-19T23:07:10+0000 weekly 0.8 https://9690a.iqanda-cme.com/videos/what-unique-aspects-with-respect-to-all-cause-mortality-outcomes-and-baseline-ldl-c-levels-were-observed-in-the-odyssey-outcomes-trial-and-how-would-you-translate-these-results-into-patient-care 2019-04-13T15:25:57+0000 weekly 0.8 https://9690a.iqanda-cme.com/videos/since-both-pcsk9-outcome-trials-demonstrated-impressive-safety-when-ldl-c-levels-are-lowered-into-ranges-much-lower-than-70-mg/dl-what-should-be-the-approach-of-the-interventional-and-medical-cardiologist-to-achieving-ldl-c-levels-in-thi1 2019-03-19T22:56:48+0000 weekly 0.8 https://9690a.iqanda-cme.com/videos/what-other-markers-besides-ldl-c-levels-do-you-believe-we-should-consider-to-refine-cv-risk-stratification 2019-04-13T15:30:57+0000 weekly 0.8 https://9690a.iqanda-cme.com/videos/as-a-leading-authority-in-ldl-c-mediated-cv-risk-reduction-can-you-provide-us-with-your-perspective-on-the-evidence-for-pcsk9-inhibitors-as-a-foundational-approach-for-managing-a-broad-spectrum-of-patients-with-high-risk-coronary-heart-d5 2019-03-20T20:56:54+0000 weekly 0.8 https://9690a.iqanda-cme.com/videos/how-do-you-identify-progressing-patients-with-high-cv-risk-in-whom-pcsk9-therapy-represents-a-game-changing-strategy 2019-04-13T15:32:10+0000 weekly 0.8 https://9690a.iqanda-cme.com/videos/in-your-interventional-cardiology-practice-which-markers-of-risk-in-the-patient-who-has-undergone-a-pci-do-you-focus-on-to-promote-consideration-for-using-a-pcsk9-inhibitor1 2019-03-19T23:14:49+0000 weekly 0.8 https://9690a.iqanda-cme.com/videos/can-you-discuss-the-importance-of-the-two-principal-psck9-cv-outcome-trials-odyssey-outcomes-and-fourier-and-how-they-are-similar-and-in-what-ways-they-are-different-what-are-the-implications-for-the-patient-with-t2d-and-ascvd1 2019-03-20T00:06:31+0000 weekly 0.8 https://9690a.iqanda-cme.com/videos/what-did-odyssey-outcomes-and-fourier-teach-us-about-high-risk-patients-with-diabetes-and-the-relative-favorability-of-their-responses-to-ldl-c-lowering-with-pcsk9-inhibitors3 2019-03-20T21:18:38+0000 weekly 0.8 https://9690a.iqanda-cme.com/videos/although-the-aha-guidelines-emphasize-cv-risk-and-mortality-reductions-with-statins-odyssey-outcomes-provides-comparable-evidence-for-alirocumab-how-compelling-is-the-evidence-for-pcsk9-inhibition-as-a-mediator-of-cv-risk-and-mortality-r2 2019-03-19T22:32:13+0000 weekly 0.8 https://9690a.iqanda-cme.com/videos/with-respect-to-patients-with-hefh-and-homozygous-fh-who-are-challenged-with-lifelong-cv-disease-risk-burden-due-to-genetic-risk-what-role-do-you-believe-pcsk9-inhibitors-should-play-especially-in-younger-patient-populations1 2019-03-19T23:22:37+0000 weekly 0.8 https://9690a.iqanda-cme.com/videos/how-has-our-knowledge-of-the-safety-and-efficacy-of-pcsck9-inhibitors-evolved-and-how-has-the-odyssey-outcomes-treat-to-target-trial-helped-us-translate-these-advances-into-the-front-lines-of-interventional-cardiology-practice 2019-04-13T15:28:48+0000 weekly 0.8 https://9690a.iqanda-cme.com/videos/can-you-drill-down-into-the-specific-results-of-the-odyssey-outcomes-trial-that-demonstrate-unique-significant-reductions-in-associated-all-cause-mortality-and-how-these-findings-might-be-relevant-to-the-interventional-cardiologist 2019-04-13T15:26:41+0000 weekly 0.8 https://9690a.iqanda-cme.com/videos/from-the-view-of-an-interventional-cardiologist-and-a-lipid-medicine/atherosclerosis-specialist-can-you-discuss-what-ldl-c-thresholds-vs-clinical-burden/clinical-history-thresholds-are-important-for-patient-selection-for-pcsk9-based-risk 2019-04-13T15:32:34+0000 weekly 0.8 https://9690a.iqanda-cme.com/videos/what-has-been-your-experience-with-respect-to-patient-satisfaction-discontinuation-rates-and-toleration-of-this-injection-based-approach-to-ldl-c-management1 2019-03-19T23:01:29+0000 weekly 0.8 https://9690a.iqanda-cme.com/videos/as-the-director-of-the-center-for-cardiovascular-disease-prevention-what-patient-types-on-the-risk-landscape-of-ascvd-do-you-believe-deserve-special-attention-because-they-are-likely-to-be-eligible-candidates-for-pcsk9-mediated-ldl-c-red5 2019-03-20T17:01:54+0000 weekly 0.8 https://9690a.iqanda-cme.com/videos/what-should-the-approach-be-in-patients-who-have-had-a-coronary-event-with-an-ldl-c-level-of-70-mg/dl-do-the-outcome-studies-with-pcsk9-inhibitors-provide-an-evidentiary-roadmap-for-this-common-situation3 2019-03-20T21:26:53+0000 weekly 0.8 https://9690a.iqanda-cme.com/videos/in-light-of-the-recent-results-showing-a-reduction-in-associated-all-cause-mortality-in-the-odyssey-outcomes-trial-which-patients-deserve-our-greatest-attention-to-optimize-the-translational-impact-of-this-study1 2019-03-19T22:47:58+0000 weekly 0.8 https://9690a.iqanda-cme.com/videos/you-have-identified-the-challenges-of-accessing-pcsk9-inhibitors-for-patients-whose-cv-risk-is-genetic-vs-those-whose-clinical-course-is-characterized-by-progressive-vascular-events-how-do-you-approach-each-subset-with-respect-to-ldl-c-m 2019-04-13T15:32:58+0000 weekly 0.8 https://9690a.iqanda-cme.com/videos/based-on-the-odyssey-outcomes-and-fourier-trials-which-patient-populations-including-individuals-with-t2d-do-you-believe-should-be-targeted-for-pcsk9-inhibitors1 2019-03-20T00:18:29+0000 weekly 0.8 https://9690a.iqanda-cme.com/videos/in-the-interventional-cardiology-setting-what-percentage-of-your-patients-do-not-achieve-the-esc-lipid-guideline-goal-of-70-mg/dl-and-therefore-are-suitable-candidates-for-pcsk9-inhibition-can-you-discuss-your-patient-selection-process 2019-04-13T15:24:09+0000 weekly 0.8 https://9690a.iqanda-cme.com/videos/what-have-we-learned-from-the-odyssey-outcomes-pharmacoeconomic-analysis-that-you-and-professor-deepak-bhatt-reported-at-the-aha-2018-meeting-and-what-are-the-implications-for-the-clinician-cardiologist-who-is-making-the-case-to-payors3 2019-03-20T21:21:47+0000 weekly 0.8 https://9690a.iqanda-cme.com/videos/from-an-interventional-cardiology-perspective-what-did-odyssey-outcomes-teach-us-about-the-large-subgroup-of-diabetic-patients-who-had-acs-plus-stent-insertions 2019-04-13T15:24:53+0000 weekly 0.8 https://9690a.iqanda-cme.com/videos/in-a-high-risk-patient-who-has-undergone-multiple-stent-procedures-what-criteria-do-you-prioritize-for-initiating-a-pcsk9-inhibitor-in-the-setting-of-pci-and-what-absolute-ldl-c-targets-are-in-your-cross-hairs-based-on-the-odyssey-outcom 2019-04-13T15:29:21+0000 weekly 0.8 https://9690a.iqanda-cme.com/videos/a-confluence-of-events-has-reshaped-the-accessibility-evidence-basis-and-actionability-profile-for-pcsk9-inhibitors-as-an-atherosclerosis-specialist-how-have-these-developments-changed-the-equation-and-shaped-your-approach-to-cv-risk-red2 2019-03-19T18:03:01+0000 weekly 0.8 https://9690a.iqanda-cme.com/videos/since-esc-and-acc/aha-are-examining-hard-ldl-c-targets-for-patients-at-risk-for-ascvd-how-does-odyssey-outcomes-help-inform-cardiologists-about-the-rationale-for-pcsk9-mediated-lowering-to-achieve-ultra-low-levels-i-e-50-mg/dl-of-ldl-c 2019-04-13T15:26:19+0000 weekly 0.8 https://9690a.iqanda-cme.com/videos/can-you-discuss-the-esc-guidelines-for-ldl-c-targets-and-the-recent-aha-guidelines-designating-a-target-threshold-of-70-mg/dl-is-this-low-enough-what-is-your-recommendation-for-pcsk9-inhibition-in-the-high-risk-acs-patient-who-has-underg1 2019-03-19T23:11:08+0000 weekly 0.8 https://9690a.iqanda-cme.com/videos/can-you-help-us-de-convolute-what-is-more-important-a-the-absolute-level-of-ldl-c-level-attained-among-patients-in-the-odyssey-outcomes-trial-or-b-the-delta-i-e-the-relative-change-from-baseline-ldl-c-level-at-time-of-entry-into-the-tria 2019-04-13T15:27:27+0000 weekly 0.8 https://9690a.iqanda-cme.com/videos/ic-and-lipid-specialists-are-challenged-to-maximize-cv-risk-reduction-in-high-risk-populations-how-should-they-approach-the-70-mg/dl-ldl-c-target-identified-in-the-aha-guidelines-and-when-is-the-30-mg/dl-70-mg/dl-even-more-desirable 2019-04-13T15:31:49+0000 weekly 0.8 https://9690a.iqanda-cme.com/videos/from-an-ic-perspective-in-a-patient-who-is-post-pci/post-stent-insertion-for-acs-when-is-the-aggregated-risk-of-the-patient-sufficiently-alarming-for-you-to-consider-intensive-lowering-of-ldl-c-to-a-level-50-mg/dl-with-a-pcsk9-inhibitor 2019-04-13T15:21:54+0000 weekly 0.8 https://9690a.iqanda-cme.com/videos/how-exactly-did-you-and-your-colleagues-model-the-pharmacoeconomic-effectiveness-of-alirocumab-based-on-the-actual-results-of-the-odyssey-outcomes-trial3 2019-03-20T16:28:58+0000 weekly 0.8 https://9690a.iqanda-cme.com/videos/what-should-the-ideal-target-ldl-c-be-in-the-type-2-diabetes-population-and-what-is-the-advantage-of-the-treat-to-target-strategy-employed-in-odyssey-outcomes-and-what-did-we-learn-about-associated-all-cause-mortality-with-alirocumab-in-1 2019-03-20T00:08:25+0000 weekly 0.8 https://9690a.iqanda-cme.com/videos/what-has-been-your-clinical-experience-with-respect-to-the-comparative-toleration-of-statins-vs-pcsk9-inhibitors1 2019-03-19T23:18:40+0000 weekly 0.8 https://9690a.iqanda-cme.com/videos/if-someone-is-more-than-12-months-out-after-an-acs-event-and-currently-has-a-stent-would-you-still-consider-them-to-be-eligible-for-pcsk9-therapy-to-lower-ldl-c-and-residual-cv-risk 2019-04-13T15:24:32+0000 weekly 0.8 https://9690a.iqanda-cme.com/videos/although-70-mg/dl-is-the-target-threshold-identified-by-both-esc-and-aha-should-the-interventionalist-in-a-patient-who-has-just-undergone-a-pci-and-has-an-ldl-c-of-69-mg/dl-be-considered-adequately-cv-risk-mitigated2 2019-03-19T22:16:16+0000 weekly 0.8 https://9690a.iqanda-cme.com/videos/professor-bhatt-you-presented-the-pharmacoeconomic-in-trial-analysis-for-alirocumab-based-on-the-odyssey-outcomes-trial-can-you-discuss-the-clinical-implications-of-your-analysis-and-how-reduced-costs-for-alirocumab-will-affect-ic-practi 2019-04-16T18:12:26+0000 weekly 0.8 https://9690a.iqanda-cme.com/videos/how-should-the-fact-that-cv-risk-is-not-binary-but-progressive-influence-the-decision-to-use-a-pcsk9-inhibitor2 2019-03-19T22:10:52+0000 weekly 0.8 https://9690a.iqanda-cme.com/videos/how-have-the-2016-canadian-cardiovascular-society-guidelines-for-ldl-c-reduction-positioned-their-recommendations-for-ldl-c-target-goals-and-how-do-you-anticipate-these-might-change-in-the-future-based-on-the-odyssey-outcomes-and-fourier3 2019-03-20T21:15:46+0000 weekly 0.8 https://9690a.iqanda-cme.com/videos/within-the-context-of-the-esc-and-u-s-guidelines-for-ldl-c-reduction-which-recommend-70-mg/dl-as-a-threshold-target-how-should-we-view-the-cholesterol-landscape-between-20-mg/dl-and-70-mg/dl-in-light-of-the-odyssey-outcomes-trial1 2019-03-19T23:27:05+0000 weekly 0.8 https://9690a.iqanda-cme.com/videos/how-do-you-approach-the-diabetic-patient-who-also-has-a-constellation-of-multiple-high-risk-features-above-and-beyond-the-underlay-of-diabetes-what-is-the-relative-and-absolute-benefit-of-employing-pcsk9-inhibitors-in-this-patient-popula3 2019-03-20T16:22:40+0000 weekly 0.8 https://9690a.iqanda-cme.com/videos/based-on-odyssey-outcomes-for-which-biological/metabolic-risk-markers-do-you-feel-that-cardiologists-and-atherosclerosis-specialists-should-strive-to-achieve-ldl-c-levels-even-more-aggressive-than-those-identified-in-the-aha-guidelines5 2019-03-20T16:58:22+0000 weekly 0.8 https://9690a.iqanda-cme.com/videos/what-ldl-c-target-goals-should-a-consulting-or-treating-medical-cardiologist-recommend-for-patients-with-type-2-diabetes-with-a-known-acs-event-vs-diabetes-alone-as-a-risk-factor1 2019-03-20T21:23:20+0000 weekly 0.8 https://9690a.iqanda-cme.com/videos/based-on-odyssey-outcomes-and-fourier-what-are-the-findings-and/or-biologic-risk-features-lp-a-for-example-in-patients-managed-in-an-interventional-cardiology-setting-that-would-make-you-advocate-for-the-use-of-pcsk9-inhibitors 2019-04-13T15:25:37+0000 weekly 0.8 https://9690a.iqanda-cme.com/videos/since-the-overwhelming-majority-of-post-acs-patients-in-odyssey-outcomes-had-pci-as-part-of-their-acs-management-what-have-we-learned-about-the-safety-and-efficacy-of-alirocumab-in-this-stent-rich-population-of-high-risk-patients 2019-04-13T15:23:50+0000 weekly 0.8 https://9690a.iqanda-cme.com/videos/can-you-discuss-the-reductions-in-mace-events-reported-in-the-pcsk9-outcome-trials-and-how-they-shape-the-benefit/safety-equation-for-the-use-of-alirocumab-and-evolocumab-in-high-risk-patients-including-diabetics-for-secondary-prevention1 2019-03-19T23:58:34+0000 weekly 0.8 https://9690a.iqanda-cme.com/videos/as-an-interventional-cardiologist-in-the-uk-what-do-the-results-from-the-odyssey-outcomes-trial-and-price-reductions-mean-to-the-clinician-at-the-front-lines-of-cardiology-care-as-far-as-access-to-and-triggers-for-deploying-a-pcsk9-inhib2 2019-03-19T22:13:20+0000 weekly 0.8 https://9690a.iqanda-cme.com/videos/from-a-medical-cardiologist-and-acs-expert-perspective-can-you-identify-which-patients-should-undergo-consideration-for-pcsk9-mediated-ldl-c-reduction-and-what-risk-factors-should-encourage-cv-specialists-to-pursue-pcsk9-based-therapies3 2019-03-20T16:16:30+0000 weekly 0.8 https://9690a.iqanda-cme.com/videos/as-an-ic-you-are-seeing-post-acs/post-pci-patients-whose-atherosclerotic-disease-burden-is-exceptional-and-potentially-amenable-to-pcsk9-mediated-cv-risk-reduction-where-is-your-specific-focus-for-using-these-agents-in-this-population2 2019-03-19T22:43:50+0000 weekly 0.8 https://9690a.iqanda-cme.com/videos/interventional-cardiologists-have-a-strong-incentive-to-use-pcsk9-inhibitors-in-many-high-risk-patients-but-real-world-factors-such-as-cost-can-present-barriers-to-optimizing-cv-risk-prevention-can-you-discuss-this-and-its-relevance-to-t 2019-04-13T15:29:43+0000 weekly 0.8 https://9690a.iqanda-cme.com/videos/from-the-specific-vantage-point-of-the-interventional-cardiologist-based-on-the-results-of-the-odyssey-outcomes-trial-which-patients-who-have-undergone-pci-do-you-believe-are-the-best-candidates-for-pcsk9-therapy 2019-04-13T15:27:50+0000 weekly 0.8 https://9690a.iqanda-cme.com/videos/what-do-we-know-from-the-sub-analyses-of-the-odyssey-outcomes-trial-that-looked-at-patients-with-ldl-c-levels-below-50-mg/dl-which-of-these-based-on-baseline-ldl-c-levels-derived-disproportionate-mortality-reduction-benefit-from-alirocum 2019-04-13T15:23:24+0000 weekly 0.8 https://9690a.iqanda-cme.com/courses/iqanda-pcsk9-cardiovascular-medicine-intelligence-zone 2023-04-14T03:38:06+0000 weekly 0.8 https://9690a.iqanda-cme.com/flexpaper/applicability-and-cost-implications-for-pcsk9-inhibitors-based-on-the-odyssey-outcomes-trial 2019-03-28T01:15:38+0000 weekly 0.8 https://9690a.iqanda-cme.com/flexpaper/infographic-nla-expert-panel-pcsk9-recommendations 2019-03-28T01:15:00+0000 weekly 0.8 https://9690a.iqanda-cme.com/flexpaper/2016-esc/eas-guidelines-for-the-management-of-dyslipidaemias 2019-03-28T01:15:52+0000 weekly 0.8 https://9690a.iqanda-cme.com/flexpaper/nla-expert-panel-pcsk9-recommendations 2019-03-28T01:15:12+0000 weekly 0.8 https://9690a.iqanda-cme.com/flexpaper/2018-aha/acc-guideline-on-the-management-of-blood-cholesterol 2019-03-28T01:16:04+0000 weekly 0.8 https://9690a.iqanda-cme.com/flexpaper/pooled-analysis-of-10-odyssey-trials-comparing-reductions-in-atherogenic-lipids-and-major-cv-events 2019-03-28T01:15:25+0000 weekly 0.8 https://9690a.iqanda-cme.com/flexpaper/program-agenda-and-complete-faq-list 2019-03-28T01:16:35+0000 weekly 0.8 https://9690a.iqanda-cme.com/flexpaper/the-odyssey-outcomes-trial-topline-results-alirocumab-in-patients-after-acute-coronary-syndrome 2019-03-28T01:16:20+0000 weekly 0.8